YieldMax DIS期权收益策略主动型ETF DISO 深 沪
已收盘 06-15 16:00:00 美东时间
9.455
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 9.455
- 总市值 425.48万
- 52周最高 11.1927
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 8.8162
- 委 比 0.00%
- 总股本 45.00万
- 历史最高 11.8295
- 量 比 0
- 振 幅 0.00%
- 历史最低 5.3793
- 每 手 1
- 风险率 0.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Modison Publishes 43rd AGM Notice, Highlights Governance Compliance
Modison Limited ( ($IN:MODISONLTD) ) has shared an announcement. Modison Limite...
06-30 13:53
BRIEF-Insilico Medicine And SK Biopharmaceuticals Collaborate On Drug Discovery For Neuroimmune Disorders
BRIEF-Insilico Medicine And SK Biopharmaceuticals Collaborate On Drug Discovery For Neuroimmune Disorders June 22 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK : INSILICO MEDICINE AND SK BIOPHARMACEUTICALS ACHIEVED AI-POWERED DRUG DISCOVERY COLLABORATION WORTH UP TO 2.5 BILLION FOR NEUROIMMUNE
06-22 12:41
BRIEF-EMA's PRAC Agrees On DHPC For Tavneos On Reinforced Liver Monitoring Requirements
BRIEF-EMA's PRAC Agrees On DHPC For Tavneos On Reinforced Liver Monitoring Requirements June 12 (Reuters) - EMA's PRAC: EMA'S PRAC: CONCLUDES EVIDENCE OF POTENTIAL RISK OF NEURODEVELOPMENTAL DISORDERS IN CHILDREN BORN TO MEN TREATED WITH VALPROATE IS INCONSISTENT EMA'S PRAC: RECOMMENDED CHIKUNGUNYA
06-12 20:05
BRIEF-Incyte Nears Up To $2 Billion Deal For Blood Disorder Biotech Star - FT
BRIEF-Incyte Nears Up To $2 Billion Deal For Blood Disorder Biotech Star - FT June 7 (Reuters) - INCYTE NEARS UP TO $2BN DEAL FOR BLOOD DISORDER BIOTECH STAR - FT Source text: [ https://tinyurl.com/4fdjr644 ] Further company coverage: INCY.O (( Reuters.Briefs@thomsonreuters.com ;))
06-07 18:08
ETF Boom Turns To Shakeout As Defiance, YieldMax Close Multiple Funds
Defiance and YieldMax are closing six ETFs as the U.S. ETF market tops 5,000 funds, highlighting growing pressure on smaller products.
06-03 06:21
Ensysce Biosciences Has Been Granted European Patent Number EP3934635 Titled "COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF (FOR THE TREATMENT OR PREVENTION OF ATTENTION DEFICIT DISORDER (ADHD))"
https://data.epo.org/publication-server/publications/pdf?path=2026/21/DOC/EPNWB1/EP20767314NWB1/EP20767314NWB1.pdf
05-21 03:59
Italy - Factors to watch on May 7
Italy - Factors to watch on May 7 The following factors could affect Italian markets on Thursday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . POLITICS U.S. Se
05-07 12:00
BRIEF-Clearmind Medicine Files Patent Application In India For Next-Gen Psychedelic Compounds To Treat Mental Health Disorders
BRIEF-Clearmind Medicine Files Patent Application In India For Next-Gen Psychedelic Compounds To Treat Mental Health Disorders Clearmind Medicine Inc CMND.O : CLEARMIND MEDICINE FILES PATENT APPLICATION IN INDIA FOR NEXT-GEN PSYCHEDELIC COMPOUNDS TO TREAT MENTAL HEALTH DISORDERS Source text: ID:nGNX
03-27 19:45
BRIEF-Oryzon Gets US Patent Allowance For Vafidemstat
BRIEF-Oryzon Gets US Patent Allowance For Vafidemstat March 25 (Reuters) - Oryzon Genomics SA ORY.MC : STRENGTHENS VAFIDEMSTAT PATENT PORTFOLIO WITH U.S. NOTICE OF ALLOWANCE U.S. PATENT EXPECTED TO REMAIN IN FORCE UNTIL AT LEAST 2040, EXCLUDING ANY POTENTIAL PATENT TERM ADJUSTMENTS OR EXTENSIONS PAT
03-25 14:29
BRIEF-Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General Hospital
BRIEF-Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General Hospital March 16 (Reuters) - Alzamend Neuro Inc ALZN.O : ALZAMEND NEURO INITIATES PHASE II CLINICAL TRIAL OF AL001 "LITHIUM IN BRAIN
03-16 20:17
